Table 1 Study characteristics
Study | Country | Population | Sample size | Study type (response rate) | Age (years) | Follow-up time |
|---|---|---|---|---|---|---|
Kimman et al. 2010 [27] | Netherlands | Breast Cancer | 331 | Telephone (59%) | 58 | The first year after treatment 14Â months (range 4 to 24Â months) |
Bessen et al. 2014 [28] | Australia | Breast Cancer | 722 | Online or paper (86.4%) | 40–60 | After completion of primary treatment (surgery, radiotherapy and chemotherapy) |
Damery et al. 2014 [8] | UK | Soft Tissue Sarcoma | 132 | Face-to-face survey (47%) | 63 | After primary treatment |
Murchie et al. 2016 [29] | UK | Melanoma, Breast, Prostate or Colorectal Cancer | 668 | Questionnaires mailed (56.6%) | Under 40: 3.0% 41–50: 11.4% 51–60: 22.0% 61–70: 32.8% 71–80: 26.3% Over 81: 4.5% | Time since diagnosis: Under 1 year: 1.1% 1–2 years: 16.8% 2–5 years: 55.0% Over 5 years: 27.1% |
Wong et al. 2016 [32] | Australia | Cancer | 512 | Questionnaires mailed (36%) | 61 | The mean time since cancer diagnosis was 34Â months |
Van et al. 2021 [30] | Netherlands | Basal Cell Carcinoma (BCC) | 266 | Questionnaires mailed (21%) | 67.2 | Presenting at the dermatologists with a lesion that was clinically suspicious of BCC or recent biopsy confirmed BCC |
Li et al. 2022 [10] | China | Gastric Cancer | 376 | Face-to-face survey (85%) | 18–40: 6.12% 40–49: 25.80% 50–59: 28.19% 60–69: 26.06%  ≥ 70: 13.83 | After completed the main treatment (surgery, radiotherapy, and chemotherapy) |
Geng et al. 2024 [31] | China | Breast Cancer, Prostate Cancer, Colorectal Cancer | 422 | Face-to-face survey (95%) | 70.81 | Recipient of any primary treatment, i.e. surgery, chemotherapy, or radiotherapy |
Senanayake et al. 2024 [6] | Australia | Breast Cancer | 123 | Online survey (8%) | 26–45: 13.5% 46–55: 25.4% 56–65: 31.7% 66–75: 25.4% 75 + : 4.0% | Completed treatment within the last five years |